Dovonex is a drug owned by Leo Pharma As. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 09, 2015. Details of Dovonex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| USRE39706 | Crystalline form of a vitamin D analogue |
Jun, 2015
(10 years ago) |
Expired
|
| US5763426 | Crystalline form of a vitamin D analogue |
Jun, 2015
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Dovonex's patents.
Latest Legal Activities on Dovonex's Patents
Given below is the list of recent legal activities going on the following patents of Dovonex.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 26 Jun, 2007 | USRE39706 |
| Electronic Review | 09 Jun, 2007 | USRE39706 |
| Email Notification | 08 Jun, 2007 | USRE39706 |
| Issue Notification Mailed | 08 Jun, 2007 | USRE39706 |
| Receipt into Pubs | 09 May, 2007 | USRE39706 |
| Dispatch to FDC | 08 May, 2007 | USRE39706 |
| Dispatch to FDC | 03 May, 2007 | USRE39706 |
| Application Is Considered Ready for Issue | 07 Mar, 2007 | USRE39706 |
| Dispatch to FDC | 07 Mar, 2007 | USRE39706 |
| Issue Fee Payment Received | 19 Dec, 2006 | USRE39706 |
US patents provide insights into the exclusivity only within the United States, but
Dovonex is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Dovonex's family patents as well as insights into
ongoing legal events
on those patents.
Dovonex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dovonex's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 09, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dovonex Generic API suppliers:
Calcipotriene is the generic name for the brand Dovonex. 6 different companies have already filed for the generic of Dovonex, with Chartwell Rx having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Dovonex's generic
How can I launch a generic of Dovonex before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Dovonex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Dovonex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Dovonex -
| Strength | Submission Date | Expiration Date of Last Qualifying Patent | 180-Day Status | First Applicant Approval | Generic Competition Status |
|---|---|---|---|---|---|
| 02 Dec, 2009 | 09 Jun, 2015 | Eligible | 30 May, 2012 | Less | |
| 19 May, 2006 | 09 Jun, 2015 | Eligible | 06 May, 2008 | Less |
Alternative Brands for Dovonex
There are several other brand drugs using the same active ingredient (Calcipotriene) as Dovonex. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Calcipotriene, Dovonex's active ingredient. Check the complete list of approved generic manufacturers for Dovonex
About Dovonex
Dovonex is a drug owned by Leo Pharma As. Dovonex uses Calcipotriene as an active ingredient. Dovonex was launched by Leo in 1996.
Approval Date:
Dovonex was approved by FDA for market use on 22 July, 1996.
Active Ingredient:
Dovonex uses Calcipotriene as the active ingredient. Check out other Drugs and Companies using Calcipotriene ingredient
Dosage:
Dovonex is available in the following dosage forms - cream form for topical use, solution form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.005% | CREAM | Prescription | TOPICAL |
| 0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION | Discontinued | TOPICAL |